Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan + KL-A167 maintenance in ES-SCLC after first-line chemoimmunotherapy
ChiCTR2500104246Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and tagitanlimab in small cell lung cancer (SCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Progression-free survival, Objective response rate and 1 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecantagitanlimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500104246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104246.